4GRINYO J M, CRUZADO J M. Cyclosporine nephrotoxicity [J]. Transplant Proc, 2004, 36 (2 Suppl) : 240S- 242S.
5Ruskone-Fourmestraux A, Dragosics B, Morgner A, et al. Paris staging system for primary gastrointestinal lymphomas.Gut. 2003; 52(6):912-913.
6Sun H, Subbotin V, Chen C, et al. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody.Transplantation. 1997; 64(12):1838-1843.
7Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways.Nature.1996; 381 (6581):434-438.
8Mach F, Schonbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997; 94(5): 1931 - 1936.
9van Kooten C, Gerritsma JS, Paape ME, et al. Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int. 1997; 51(3):711-721.
10van Kooten C, van der Linde X, Woltman AM, et al. Synergistic effect of interleukin-1 and CD40L on the activation of human renal tubular epithelial cells.Kidney Int. 1999; 56(1 ):41-51.
